Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy
N/A
20 Years
N/A
20 Years
N/A
Not Enrolling
Both
Cancer
Both
Cancer
Trial Information
Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy
Inclusion Criteria:
- At least one measurable lesion according to RECIST criteria
- Histologically or cytologically confirmed NSCLC of adeno histology
- Locally progressed or metastasized on or after first-line chemotherapy. The imaging
evidence of disease progression can be either chest X ray, CT or MRI assessment on
measurable lesions. If no measurable lesion is available, evaluable lesions are acce
Exclusion Criteria:
-
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Outcome Measure:
PFS of the third-line therapy
Outcome Time Frame:
9 months
Safety Issue:
No
Authority:
Taiwan: Institutional Review Board
Study ID:
NIS-OTW-DUM-2008/1
NCT ID:
NCT00836160
Start Date:
August 2009
Completion Date:
September 2012
Related Keywords:
- Cancer
- EGFR-TKI therapy
- NSCLC
- Efficacy
Name | Location |
|---|
